FeesSafety
Pluang+

Monte Rosa Therapeutics remains a risky Buy despite 50% share loss and pipeline challenges.

Analyst Insights
17 Nov 2026, 19:09 WIB
Seeking Alpha
View Source
Neutral
Monte Rosa Therapeutics remains a risky Buy despite 50% share loss and pipeline challenges.

Monte Rosa Therapeutics (GLUE) has seen its stock drop nearly 50% since an initial Buy rating due to setbacks like the failure of ziltivekimab, which hurt confidence in its inflammation-targeting cardiovascular drugs. Despite this, promising biomarker data from MRT-8102 supports continued research. The company holds about $580 million in cash, valuing its pipeline at roughly $215 million, but risks remain from clinical failures and cash burn. Upcoming data from MRT-6160 and MRT-2359, along with partner milestones, could provide catalysts for the stock.

Monte Rosa Therapeutics is the subject of this report, with Pluang providing a snapshot of the health sector market as of Nov 17, 2026 22:21 WIB. Out of 150 priced health-sector US stocks tradable on Pluang, 37 rose and 110 fell today. Notable movers include SLS at USD 19.27 with a 1-day change of +157.97%, SMMT at USD 10.93 down 7.57%, and NUWE at USD 4.30 down 6.93%.

More News

Ipsos discloses share buyback trades from Nov 9-13, 2026, showing steady repurchases at around €36 per share.

Ipsos discloses share buyback trades from Nov 9-13, 2026, showing steady repurchases at around €36 per share.

Ipsos reported its share buyback activity from November 9 to 13, 2026, purchasing thousands of its own shares daily on multiple trading platforms at prices near €36 each. This ongoing buyback program reflects the company's strategy to return value to...

Company Fundamentals
Neutral
56 minutes ago
Ipsos repurchased over 80,000 shares from Nov 9-13, 2026, at average prices around €36 each.

Ipsos repurchased over 80,000 shares from Nov 9-13, 2026, at average prices around €36 each.

Between November 9 and 13, 2026, Ipsos conducted a share buyback program, repurchasing a total of more than 80,000 ordinary shares across different markets. The average purchase price per share ranged around €36. This move reflects Ipsos's strategy t...

Company Fundamentals
Neutral
56 minutes ago
Lightspark launches Agent Accounts enabling AI agents to make payments globally with Visa and multiple currencies.

Lightspark launches Agent Accounts enabling AI agents to make payments globally with Visa and multiple currencies.

Lightspark has introduced Agent Accounts, a new payment solution allowing AI agents to hold, spend, send, and receive money on behalf of individuals or businesses across various currencies and payment methods. This service supports payments at over 1...

Others
Bullish
56 minutes ago
Bernstein SocGen raises Humana price target to $515 amid strong stock gains and new Gold Card program launch.

Bernstein SocGen raises Humana price target to $515 amid strong stock gains and new Gold Card program launch.

Bernstein SocGen Group has raised its price target for Humana to $515, reflecting confidence in the health insurer's strong performance. Humana shares have surged 80.1% year-to-date and recently hit a 52-week high of $462.87. The company plans to lau...

Analyst Insights
Bullish
1 hour ago
Amer Sports beats Q3 earnings estimates and raises full-year guidance on strong growth.

Amer Sports beats Q3 earnings estimates and raises full-year guidance on strong growth.

Amer Sports reported Q3 2026 earnings per share of $0.42, surpassing the analyst estimate of $0.36, with revenue of $2.17 billion beating the $2.14 billion forecast. The company saw 24% revenue growth and margin expansion, driven by strong performanc...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App